Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
BioStem TechnologiesBSEM +4.59%36 Debt-to-EBITDA is 0.56 as of Sep. 2025. GuruFocus rates BSEM with a GF Score™ of 36/100. The stock has 3 warning signs investors should review. Among 291 Biotechnology companies, BioStem Technologies ranks better than 70.1% on this metric.
Debt-to-EBITDA measures a company's ability to pay off its debt.
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
The historical rank and industry rank for BioStem Technologies's Debt-to-EBITDA or its related term are showing as below:
BSEM'
s Debt-to-EBITDA Range Over the Past 10 Years
Min: -8.03 Med: -0.67 Max: 0.34
Current: 0.34
During the past 13 years, the highest Debt-to-EBITDA Ratio of BioStem Technologies was 0.34. The lowest was -8.03. And the median was -0.67.
BSEM's Debt-to-EBITDA is ranked better than 70.1% of 291
companies
in the Biotechnology industry
Industry Median: 1.14
vs BSEM: 0.34
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.
According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
BioStem Technologies Debt-to-EBITDA Related Terms
BioStem Technologies Debt-to-EBITDA Historical Data
* Premium members only.
The historical data trend for BioStem Technologies's Debt-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BSEM vs RNTX, SPRO, ACRV: Debt-to-EBITDA Comparison
For the Biotechnology subindustry, BioStem Technologies's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
BioStem Technologies Debt-to-EBITDA vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, BioStem Technologies's Debt-to-EBITDA distribution charts can be found below:
* The bar in red indicates where BioStem Technologies's Debt-to-EBITDA falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data,
the EBITDA data used here is four times the quarterly (Sep. 2025) EBITDA data.
BioStem Technologies (BSEM) has a Debt-to-EBITDA of 0.56 as of Sep. 2025. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on BioStem Technologies. According to the industry distribution chart, BioStem Technologies ranks #87 out of 291 companies in the Biotechnology industry, placing it in the top 29.9%.
Is BioStem Technologies' Debt-to-EBITDA too high?
BioStem Technologies' current Debt-to-EBITDA is 0.56. The Biotechnology industry median Debt-to-EBITDA is 1.14. BioStem Technologies' value of 0.56 is 50.9% below this industry median. Based on the distribution chart, BioStem Technologies ranks #87 out of 291 companies in the Biotechnology industry, which is above the industry midpoint. Overall, BioStem Technologies has a GF Score™ of 36/100, reflecting its overall financial health beyond just this single metric.
How does BioStem Technologies' Debt-to-EBITDA compare to RNTX and SPRO?
According to the Biotechnology industry distribution chart, BioStem Technologies ranks #87 out of 291 companies for Debt-to-EBITDA. This puts BioStem Technologies in the upper half of its industry. The industry median Debt-to-EBITDA is 1.14. BioStem Technologies' value of 0.56 is 50.9% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-EBITDA for a Biotechnology company?
The median Debt-to-EBITDA among Biotechnology companies is 1.14, based on 291 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. BioStem Technologies's current Debt-to-EBITDA of 0.56 is 50.9% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-EBITDA mean?
A high Debt-to-EBITDA can signal that a stock is expensive relative to its fundamentals. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on BioStem Technologies. For the Biotechnology industry, the median Debt-to-EBITDA is 1.14 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. BioStem Technologies's current Debt-to-EBITDA is 0.56. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BioStem Technologies stock overvalued right now?
BioStem Technologies (BSEM) has a current Debt-to-EBITDA of 0.56. The current Debt-to-EBITDA is 0.56 and 50.9% below the Biotechnology industry median of 1.14. BioStem Technologies' overall GF Score™ is 36/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-EBITDA calculated?
Debt-to-EBITDA is calculated from a company's financial statements. For BioStem Technologies (BSEM), the current Debt-to-EBITDA is 0.56 as of Sep. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
BioStem Technologies Inc is a regenerative biotechnology company focused on harnessing elements of perinatal tissue and the body's innate biology to repair or reverse damage caused by a broad range of degenerative diseases. The company develops, manufactures, and sells tissue allografts for the wound care market with a focus on the treatment of diabetic, pressure, and venous ulcers. Utilizing its proprietary BioRetain processing method, it manufactures perinatal tissue allografts. The company offers a comprehensive portfolio of high-quality brands that are trademarked and include VENDAJE AC, AmnioWrap2, and Others. The company generates key revenue from VENDAJE AC.
36GF Score
Get the complete analysis for BSEM
Debt-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BSEM has been successfully added to your 
